Skip to content
Screener

Nurix Therapeutics, Inc. NRIX Accretion (Amortization) of Discounts and Premiums, Investments

Accretion (Amortization) of Discounts and Premiums, Investments at other companies

Arvinas logo
ArvinasARVN
$1.7M-55.3%
Septerna, Inc. logo
Septerna, Inc.SEPN
$462K-52.6%
Regenxbio logo
RegenxbioRGNX
$442K-67.4%

Other financials

Income statement

See full
Revenue$9.0M-79.5%
Operating income-$94.2M-95.0%
Net income-$89.5M-106%
EPS (diluted)-$0.81-55.8%

Balance sheet

See full
Cash & equivalents$68.7M-19.4%
Total debt$58.1M+12.0%
Total equity$402.6M-10.0%
Total assets$535.5M-9.5%

Cash flow

See full
Operating cash flow-$96.6M-52.9%
CapEx$1.9M-27.6%
Free cash flow-$98.5M-49.6%

Valuation

See full
Market cap$2.65B+259%
Enterprise value$2.64B+275%
P/S72.1×+63.7×

Profitability

See full
Operating margin-982.4%-1,538pp
Net margin-928.4%-1,403pp
FCF margin-378.7%+24.1pp

Returns & leverage

See full
Return on equity-80.3%+113pp
Debt / equity0.1×0.0×
Current ratio6.3×-0.5×

Where this comes from

Reported directly by Nurix Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments.

The source filing: Nurix Therapeutics, Inc.’s 10-Q, filed July 9, 2026.

Filed
Jul 9, 2026, 4:12 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001549595-26-000040
Line itemSix Months Ended May 31, 2026Six Months Ended May 31, 2025
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization4,4514,592
Stock-based compensation20,79219,107
Net accretion of discount on marketable securities(3,535)(6,258)
Loss on disposal of property and equipment160
Amortization of operating lease right-of-use assets3,1754,633
Changes in operating assets and liabilities:
Accounts receivable(19,000)

Item 1. Financial Statements (Unaudited)

FAQ

What is Nurix Therapeutics, Inc.'s accretion (amortization) of discounts and premiums, investments?
Nurix Therapeutics, Inc. (NRIX) reported accretion (amortization) of discounts and premiums, investments of $1.56M in Q1 2026.
How has Nurix Therapeutics, Inc.'s accretion (amortization) of discounts and premiums, investments changed year-over-year?
Nurix Therapeutics, Inc.'s accretion (amortization) of discounts and premiums, investments decreased by 42.4% year-over-year, from $2.7M to $1.56M.
What is the long-term trend for Nurix Therapeutics, Inc.'s accretion (amortization) of discounts and premiums, investments?
Over 3 years (2021 to 2025), Nurix Therapeutics, Inc.'s accretion (amortization) of discounts and premiums, investments has grown at a 82.2% compound annual growth rate (CAGR), from -$1.71M to $10.32M.
What does accretion (amortization) of discounts and premiums, investments mean?
This represents the non-cash adjustment to net income for the amortization of discounts or premiums on held-to-maturity or available-for-sale investment securities. It reflects the gradual recognition of interest income over the life of the investment, adjusting the carrying value toward par value. Investors use this to reconcile reported net income with actual cash flows generated from investment activities.

Ask your AI about Nurix Therapeutics, Inc.'s accretion (amortization) of discounts and premiums, investments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude